XOMA Royalty (NASDAQ: XOMA) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will host a live webcast on March 18, 2026 at 8:00 AM ET to discuss results and provide a business update.
According to the company, the webcast will be accessible on the Investors "News & Events" page and a replay will be available for 30 days after the live event.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – XOMAO
+0.12%
+0.12%Session close to close
In the Mar 12 session, XOMAO gained 0.12%, reflecting a mild positive market reaction.
This announcement sets expectations for XOMA Royalty’s fourth quarter and full-year 2025 results on ...
Analysis
This announcement sets expectations for XOMA Royalty’s fourth quarter and full-year 2025 results on March 18, 2026, with a webcast at 8:00 am Eastern Time and a replay available for 30 days. Ahead of this event, the stock traded slightly below its 52-week high and near the 200-day moving average. Recent history shows only modest price reactions to news on acquisitions, royalty restructurings, and management changes, so investors may focus on the forthcoming financial details and any updated strategic commentary.
Key Figures
Earnings date:March 18, 2026Webcast time:8:00 am Eastern TimeWebcast replay period:30 days+5 more
8 metrics
Earnings dateMarch 18, 2026Scheduled Q4 and full-year 2025 results release
Webcast time8:00 am Eastern TimeEarnings webcast on March 18, 2026
Webcast replay period30 daysAvailability of earnings webcast replay
Generation Bio cash consideration$4.2913 per shareCash portion of consideration in Generation Bio tender offer
Shares tendered4,722,533 sharesGeneration Bio shares validly tendered (~70%)
Mezagitamab milestones (new)up to $13.0 millionPotential milestones retained under amended Takeda agreement
Series A dividend$0.53906 per shareQuarterly dividend for 8.625% Series A preferred
Series B depositary dividend$0.52344 per depositary shareQuarterly dividend for 8.375% Series B depositary shares
Declared quarterly cash dividends on Series A and Series B preferred securities.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news items, including M&A, strategic deals, and management changes, have been followed by very small price moves, suggesting historically muted trading reactions to corporate developments.
Recent Company History
Over the past few months, XOMA Royalty reported several corporate developments, including investor conference presentations on Mar 2 and Mar 11, 2026, completion of the Generation Bio acquisition with cash and CVR consideration on Feb 9, 2026, and a CFO transition announced on Jan 12, 2026. Earlier, it restructured mezagitamab economics with Takeda on Dec 30, 2025 and declared quarterly preferred and depositary share dividends on Dec 22, 2025. Each event saw only modest share price reactions.
"stockholders received $4.2913 per share in cash plus one non-tradeable contingent value right (CVR)."
A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.
tender offerfinancial
"announced it completed its tender offer and acquisition of Generation Bio, Inc."
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
"8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP)"
A cumulative perpetual preferred stock is a share that acts like a long-lasting hybrid between a bond and a dividend-paying stock: it promises regular fixed payments that, if missed, accumulate and must be paid later before common shareholders get dividends, and it has no set maturity date. Investors care because it can provide steady, higher-priority income similar to interest, but with limited capital upside, sensitivity to interest rates, and the risk that payments can be delayed even though they continue to accrue.
depositary sharefinancial
"$0.52344 per depositary share for depositary shares representing 1/1000 of the 8.375% Series B"
A depositary share is a special type of stock that represents ownership in a company but is traded on the stock market like regular shares. It often makes it easier for people to buy and sell shares of companies from other countries or smaller companies that don’t list directly on big exchanges.
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the results and provide a business update.
The webcast will be accessible on the “News & Events” page in the Investors section of XOMA Royalty’s website (www.investors.xoma.com/news-events). A replay of the webcast will be available for 30 days following the live event.
About XOMA Royalty Corporation XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
Investor contact:
Media contact:
Juliane Snowden
Kathy Vincent
XOMA Royalty Corporation
KV Consulting & Management
+1-646-438-9754
kathy@kathyvincent.com
juliane.snowden@xoma.com
FAQ
When will XOMA (NASDAQ: XOMA) release Q4 and full year 2025 results?
XOMA will release fourth quarter and full year 2025 results on March 18, 2026. According to the company, a webcast discussing the results and a business update will begin at 8:00 AM Eastern Time that same day.
How can investors access XOMA's March 18, 2026 webcast about 2025 results?
Investors can access the live webcast via XOMA's Investors "News & Events" page on its website. According to the company, the webcast link will be posted there and a replay will be available for 30 days after the live event.
What time is XOMA's webcast for the Q4 and full year 2025 results on March 18, 2026?
The webcast is scheduled for 8:00 AM Eastern Time on March 18, 2026. According to the company, management will discuss the financial results and provide a business update during the live presentation and Q&A.
Will XOMA provide a replay of the March 18, 2026 webcast for Q4 and 2025 results?
Yes, XOMA will provide a replay of the March 18, 2026 webcast for 30 days following the live event. According to the company, the replay will be accessible on the Investors "News & Events" page on its website.
Where is XOMA (XOMA) hosting the investor webcast for its 2025 results and business update?
XOMA is hosting the investor webcast on its corporate website under the Investors "News & Events" section. According to the company, the page will include the live link and a replay available for 30 days after the event.
